ADCAN Pharma has partnered with Menarini, an Italy-based pharmaceutical company, to locally manufacture and release selected medicines in the UAE. The agreement, signed at ADCAN Pharma’s Abu Dhabi facility, aims to improve medicine availability, strengthen supply chain resilience, and provide faster access to critical therapies for patients.
The collaboration marks Menarini’s first pharmaceutical localisation initiative in the UAE and supports the country’s vision of building a sustainable and self-sufficient healthcare ecosystem. ADCAN Pharma will leverage its advanced manufacturing and regulatory capabilities to support production while expanding its role as a regional pharmaceutical hub.
Also read: Vertex Presents New CASGEVY Data in Children, Expands Global Regulatory Filings
Dr Fokion Sinis, Chief Executive Officer of ADCAN Pharma, said, “This partnership with Menarini aligns with our long-standing mission to strengthen the UAE’s pharmaceutical manufacturing landscape. Moreover, by combining Menarini’s global expertise with ADCAN Pharma’s advanced manufacturing and batch-release capabilities, we are supporting the national vision to nurture a resilient and sustainable pharmaceutical ecosystem. The collaboration also reinforces our role as a trusted local manufacturing partner for international pharmaceutical companies while facilitating improved access to high-quality medicines across the region.”
The partnership is expected to enhance local manufacturing capacity, create new growth opportunities, and contribute to the goals of We the UAE 2031 by strengthening the nation’s pharmaceutical industry.
